

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference are made to the announcements of Wai Chun Bio-Technology Limited (the “**Company**”) dated 12 December 2025 and 6 January 2026 (the “**Announcements**”) in relation to (1) the Loan Agreement entered into between the Company and the Borrower; and (2) non-compliance with the Listing Rules. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, the Circular containing, among others, further details of the Drawdowns, is expected to be despatched to the Shareholders no later than 27 January 2026. As additional time is required for the Company to prepare and finalise certain financial information to be included in the Circular, the despatch date of the Circular has been postponed to on or before 25 February 2026.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman and Executive Director

Hong Kong, 27 January 2026

As at the date of this announcement, the Board comprises:

Executive Director:

Mr. Lam Ka Chun (*Chairman and Chief Executive Officer*)

Independent Non-executive Directors:

Mr. Wong Po Keung

Mr. Wang Ziniu

Ms. Xu Huiling